Anavex Life Sciences (AVXL) to Release Earnings on Wednesday

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect Anavex Life Sciences to post earnings of ($0.17) per share for the quarter.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.03.

Anavex Life Sciences Stock Down 3.1 %

AVXL stock traded down $0.30 during trading on Friday, hitting $9.27. The company had a trading volume of 1,513,714 shares, compared to its average volume of 1,706,670. Anavex Life Sciences has a 52-week low of $3.25 and a 52-week high of $14.44. The company has a 50 day simple moving average of $9.99 and a 200-day simple moving average of $7.56. The firm has a market capitalization of $786.28 million, a P/E ratio of -17.83 and a beta of 0.70.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a research note on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $42.00 target price on shares of Anavex Life Sciences in a research report on Tuesday.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.